Heritage Wealth Advisors purchased a new stake in shares of Clorox Co (NYSE:CLX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 197 shares of the company’s stock, valued at approximately $30,000.
Several other hedge funds have also recently modified their holdings of CLX. FTB Advisors Inc. boosted its stake in shares of Clorox by 134.7% during the 2nd quarter. FTB Advisors Inc. now owns 3,237 shares of the company’s stock worth $494,000 after acquiring an additional 1,858 shares in the last quarter. Investment House LLC boosted its position in shares of Clorox by 1.7% in the second quarter. Investment House LLC now owns 41,354 shares of the company’s stock worth $6,332,000 after buying an additional 675 shares during the period. Securian Asset Management Inc boosted its position in shares of Clorox by 0.8% in the second quarter. Securian Asset Management Inc now owns 13,416 shares of the company’s stock worth $2,054,000 after buying an additional 112 shares during the period. Meeder Asset Management Inc. boosted its position in shares of Clorox by 124.0% in the second quarter. Meeder Asset Management Inc. now owns 383 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Clorox by 50.7% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 199,275 shares of the company’s stock worth $30,511,000 after buying an additional 67,042 shares during the period. Institutional investors own 75.88% of the company’s stock.
Several brokerages have recently commented on CLX. UBS Group raised their target price on Clorox from $110.00 to $128.00 and gave the stock a “sell” rating in a research report on Friday, August 2nd. ValuEngine cut Clorox from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Deutsche Bank raised Clorox from a “sell” rating to a “hold” rating and set a $139.00 target price for the company in a research report on Thursday, May 2nd. Citigroup set a $156.00 target price on Clorox and gave the stock a “hold” rating in a research report on Thursday, May 23rd. Finally, BMO Capital Markets set a $168.00 target price on Clorox and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $154.07.
NYSE CLX traded up $0.09 during trading on Thursday, reaching $158.16. 4,989 shares of the company traded hands, compared to its average volume of 1,079,112. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.55 and a current ratio of 0.91. The stock’s 50 day moving average price is $159.46 and its two-hundred day moving average price is $155.81. The company has a market cap of $19.96 billion, a price-to-earnings ratio of 25.12, a P/E/G ratio of 5.10 and a beta of 0.37. Clorox Co has a 1-year low of $141.53 and a 1-year high of $167.70.
Clorox (NYSE:CLX) last released its quarterly earnings data on Thursday, August 1st. The company reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.69 billion. Clorox had a return on equity of 118.88% and a net margin of 13.20%. The company’s quarterly revenue was down 3.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.66 earnings per share. Equities research analysts expect that Clorox Co will post 6.4 EPS for the current fiscal year.
In other news, SVP Denise Garner sold 20,399 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $157.61, for a total value of $3,215,086.39. Following the transaction, the senior vice president now directly owns 4,896 shares of the company’s stock, valued at approximately $771,658.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director A D. David Mackay sold 3,400 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $154.87, for a total value of $526,558.00. The disclosure for this sale can be found here. Insiders sold a total of 25,786 shares of company stock worth $4,054,776 over the last three months. 1.40% of the stock is owned by company insiders.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Featured Article: What is the Stochastic Momentum Index (SMI)?
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.